Scientific Program

- Session times are Korea Standard Time (UTC/GMT+9). Please click the link and check your local time.
- Program is subject to change.
- Program will be updated continuously.
- Some sessions are in Korean.

  • Wednesday, October 26
  • Thursday, October 27
  • Friday, October 28
  • Oral Presentation
  • Education Workshop

[Pre-Congress Workshop]
Onco-day : Early diagnosis improves patients outcome

Session 01: Liver cancer marker
In this session, we would highlight the influence through the biomarkers and algorithm and explore current liver cancer practices of APAC where South Korea belongs.

Session 02: Liver disease marker
In this session, we would explore liver disease epidemiology in APAC, current practice, and the role of testing in the end-to-end liver journey. In addition to this, we would like to introduce the clinical usefulness of Elecsys HCV duo, an early diagnosis marker for hepatitis C.

Session 03: Ovarian cancer marker
We would introduce the role of ovarian cancer markers (HE4 & ROMA) in clinical practice and share the economic evaluation results of ROMA algorithms in China.

Pre-congress 01: Liver cancer marker

Date & Time Oct. 26 (Wed.), 10:30-12:00 Room Room A Language Eng
Chair(s)
  1. Myung Geun Shin, Chonnam National University College of Medicine, Korea
Speaker(s)
  1. The role of biomarkers and algorithm in the early detection of HCC
    Amit Singal, UT Southwestern Medical Center, USA
  2. PIVKA-II in HCC prognosis and treatment monitoring
    Do Young Kim, Yonsei University College of Medicine, Korea

Pre-congress 02: Liver disease marker

Date & Time Oct. 26 (Wed.), 13:00-14:20 Room Room A Language Eng
Chair(s)
  1. Dong Hee Whang, Inje University College of Medicine, Korea
Speaker(s)
  1. GAAD: a new prospect for HCC surveillance
    Irma Wang, Roche Diagnostics APAC, Singapore
  2. HCV duo for early diagnosis of Hepatitis C
    Deepika Jindal, Roche Diagnostics APAC, Singapore

Pre-congress 03: Ovarian cancer marker

Date & Time Oct. 26 (Wed.), 14:40-15:40 Room Room A Language Eng
Chair(s)
  1. Hee-Yeon Woo, Sungkyunkwan University School of Medicine, Korea
Speaker(s)
  1. Clinical usefulness of HE4 and ROMA
    Yoo Young Lee, Sungkyunkwan University School of Medicine, Korea
  2. ROMA HECON study in China
    Lei Yuan, The Obstetrics & Gynecology Hospital of Fudan University, China

[EW01]
Mindray Medical Korea

There is a limitation to accurately measuring platelets by automated hematology analyzers in samples with low platelet counts. Mindray BC6800Plus operates an optical channel (PLT-O) using nucleic acid dye for precise platelet counts. This channel is set apart from other instruments in that reagents containing specific chemicals and certain physical conditions resolve EDTA-dependent platelet clumping through depolymerization of platelet clumps. This workshop informs the performance of the PLT-O channel of Mindray BC6800Plus using EDTA-dependent pseudo thrombocytopenic samples.

Date & Time Oct. 27 (Thu.), 08:00-09:00 Room Room A Language Eng
Chair(s)
  1. Jimyung Kim, Chungnam National University Hospital, Korea
Speaker(s)
  1. Performance of the platelet measurement channel in EDTA-depedent pseudothrombocytpenic samples on Mindray BC-6800 Plus
    Sholhui Park, Ewha Womans University Seoul Hospital, Korea
  2. Mindray Hematology Solution, CAL8000 with MC-80 Image analyzer
    Wendy Li, Mindray Global Clinical Affair, China

[EW02]
SD Biosensor, Inc.

Accurate and rapid molecular diagnosis of COVID-19 is an essential step to tackle the ongoing pandemic. The objective of this study was to evaluate the real-world performance of the novel RT-PCR STANDARD M10 SARS-CoV-2 assay in a large number of nasopharyngeal (NP) specimens eluted in universal transport medium.
A total of 50 samples were analyzed. Compared with the standard extraction-based Xpress SARS-CoV-2 from Xpert and RT-PCR Novel coronavirus (2019-nCoV) Nucleic Acid diagnostic Kit from sansure, the sensitivities of the STANDARD M10 were 100% in various concentration, the specificity was 100% as well.
The diagnostic accuracy was 100% in testing both NP samples eluted in an activated transport medium. STANDARD M10 reliably detects SARS-CoV-2 in 60 min, may be used as a POC tool, and is suitable for testing LRT specimens in the critical care setting.

Date & Time Oct. 27 (Thu.), 11:50-12:50 Room Room A Language Eng
Chair(s)
  1. Mi-Kyung Lee, Chung-Ang University College of Medicine, Korea
Speaker(s)
  1. Comparative diagnostic accuracy of POC assay for the molecular diagnosis of SARS-CoV-2
    Dewi Kartika Turbawaty, Hasan Sadikin Hospital, Indonesia

[EW03]
Abbott

Procalcitonin is one of the main biomarkers for bacterial infection, which can be not only used for the differential diagnosis of various infectious disease and sepsis, but also for the monitoring of appropriate antibiotic therapy. This session will discuss the usage of procalcitonin quantification assay for antibiotics stewardship, which is a tool for quality management of antibiotic prescription, administration, with current review of Korean environment and regulations, and new medical technology approval of the usage of procalcitonin for lower respiratory tract infection.

Date & Time Oct. 27 (Thu.), 11:50-12:50 Room Room B Language Eng
Chair(s)
  1. Junghan Song, Seoul National University Bundang Hospital, Korea
Speaker(s)
  1. Utility of quantitative procalcitonin in improving patient outcomes: antibiotic stewardship
    Youngwon Nam, Assistant Medical Director, Abbott Korea, Korea

[EW04]
Siemens Healthineers Ltd.

Over the last 20 years, IT systems have taken over many routine tasks in the laboratory. While this change has been welcome from a workflow perspective, few have been able to leverage the power of IT to provide clinically relevant insights.
Laboratory IT systems are now building toward a higher level of testing by connecting multiple disciplines, interpreting visual information, and bringing artificial intelligence into workflow. This development means additional efficiency advantages for hematology, urinalysis, hemostasis, and other specialties, and also provides the laboratory a unique opportunity to develop and implement AI models to supplement routine testing.  

Date & Time Oct. 27 (Thu.), 11:50-12:50 Room Room C Language Eng
Chair(s)
  1. Kyung Eun Song, Kyungpook National University School of Medicine, Korea
Speaker(s)
  1. Beyond the numbers – merging disciplines and the power of AI applications
    Vincent Chiera, Marketing Professional for Complex Projects, Lab Digitalization Siemens Healthineers, Australia

[EW05]
Roche Diagnostics Korea

The novel cobas® pure integrated solutions is a serum work area solution designed for users with a small-to-medium workload. The instrument combines a clinical chemistry analytical unit including ISE unit with an immunochemistry analytical unit; both can be used as stand-alone analyzers or in combination as an integrated system.  

Date & Time Oct. 27 (Thu.), 11:50-12:50 Room Room D Language Eng
Chair(s)
  1. Jong-Baeck Lim, Yonsei University College of Medicine, Korea
Speaker(s)
  1. Performance evaluation of cobas pure integrated solutions
    Kai Klopprogge , MSA Functional Representative CPS Roche Diagnostics International, Switzerland

[EW06]
Seegene Inc.
Next Level of Digitalized MDx Workflow: Discover the insights of one-step solution in diagnostic analysis for integrated healthcare

As the paradigm of diagnosis changes to preventive-centered services, ease of managing big data and laborsaving workflow are crucial factors in selecting a diagnostics test method to prepare for another pandemic in the future. In this workshop, Seegene introduce SG-STATS, a software that can analyze the trends of PCR test results by period and targets, and Seegene STARlet-AIOS, a fully automated equipment that can quickly and efficiently operate molecular diagnosis. 

Date & Time Oct. 27 (Thu.), 11:50-12:50 Room Room E Language Eng
Chair(s)
  1. Yeonjoon Park, The Catholic University of Korea College of Medicine, Korea
Speaker(s)
  1. Gastrointestinal infection trends in Germany and data management through SG STATS
    Jennifer Ortelt, Helios University Hospital Wuppertal, Germany
  2. Seegene STARlet-AIOS: Brand-new full automation system of Seegene
    Jae Hyeok Choi, Strategic Product Planning & Business Development Group, Seegene Inc., Korea

[EW07]
SS Medipia

Lupus anticoagulant (LA) testing is part of the the antiphopholipid syndrome (APS)diagnosis, a disease associated with increased vascular thrombosis and pregnancy morbidity risk. LA is the best-established risk factor for APS-related clinical manifestations; accurate assessment is then crucial, but high rates of false results are reported. The multistep procedure including aPTT and dRVVT run in parallel makes LA analysis complex, with many pitfalls. An automated algorithm may contribute to improve performance. Stago developed an automated algorithm, based on expert's recommendations and ISTH guideline. The STA Coag Expert LA algorithm benefits in LA interpretation harmonization and may improve interlaboratory comparability. 

Date & Time Oct. 27 (Thu.), 13:00-14:00 Room Room D Language Eng
Chair(s)
  1. Seongsoo Jang, Asan Medical Center, Korea
Speaker(s)
  1. Lupus anticoagulant: how the implementation of an automated algorithm can make a challenging diagnosis so simple?
    François Depasse – Diagnostica Stago, Asnières sur Seine, France

[EW08]
Becton, Dickinson Company

Recent trend of CPE and molecular determination of carbapenemase genotype

Date & Time Oct. 27 (Thu.), 13:00-14:00 Room Room E Language Eng
Chair(s)
  1. SeokHoon Jeong, GangNam Severance Hospital, Korea
Speaker(s)
  1. Recent trend of CPE and molecular determination of carbapenemase genotype
    DoKyun Kim, GangNam Severance Hospital, Korea

[EW09]
QuantaMatrix Inc.

direct & Rapid Antimicrobial Susceptibility Testing (dRAST) provides MIC-based phenotypic antimicrobial susceptibility testing directly from positive blood culture. The system reduces time to results (TTR) by upto 2 days compared to the conventional methods. This session discusses the underlying technology of dRAST and demonstrates how the reduction in TTR benefits clinical microbiology labs as well as patients with blood stream infection (BSI).

Date & Time Oct. 27 (Thu.), 14:50-15:50 Room Room D Language Eng
Chair(s)
  1. SunHwa Lee, Seegene Medical Foundation, Korea
Speaker(s)
  1. Rapid Antimicrobial Susceptibility Testing of Blood Stream Infections: The Present and Future
    Sunghoon Kwon, QuantaMatrix, CEO

[EW11]
Thermo Fisher Scientific

Based on the 2018 survey on the role and usage of LC-MS/MS in Korean clinical laboratories this lecture will cover main aspects of Cascadion SM clinical analyzer value proposition
- Menu and future extensions
- Analytical performance
- Traceability and standardization of reagents and tests
- Regulatory and quality aspects
- Workflow improvements
The presentation will also address the consequences when shifting from open LC-MS/MS to Cascadion and how to leverage these.

Date & Time Oct. 27 (Thu.), 16:40-17:40 Room Room B Language Eng
Chair(s)
  1. Hyunkyung Park, Seoul Clinical Laboratories, Korea
Speaker(s)
  1. The future of easy and fast clinical next-generation sequencing is now
    Keun-Joon Park, Department of GSG, Thermo Fisher Scientific, Korea

[EW12]
SML Genetree

In this presentation, I would like to learn about next-generation sequencing (NGS), which is being used in various fields such as molecular biology, genetics research, molecular diagnosis, clinical medicine, and talk about big data and artificial intelligence (A.I.), that are receiving a lot of attention along with NGS.
  From PCR to NGS, various experimental methods have come out, and test methods using them are being used. Among them, NGS is an innovative method that can suggest various causes with one test and is used in various diagnostic tests such as oncology, genetic disease, and infectious disease.
  Finally, analysis using bioinformatics is important for NGS, and how this analysis method is developing, and large-scale genomic data research is being conducted using A.I. technology. And I would like to take time to find out the necessity and utilization of big data and A.I. in Laboratory Medicine.

Date & Time Oct. 27 (Thu.), 16:40-17:40 Room Room C Language Eng
Chair(s)
  1. Kyung A Lee, Yonsei University College of Medicine, Korea
Speaker(s)
  1. Laboratory medicine using next-generation sequencing: Beyond A.I.
    Lee Gil-Won, SML Genetree, Korea

[EW13]
Sebia Korea

Capillary Electrophoresis is a superior resolution charge-based separation method for hemoglobinopathy and HbA1c screening, overcoming poorly resolving protein fractions in traditional pressure driven column separation methods. In this talk, the principles of Capillary Electrophoresis for HbA1c measurement will be thoroughly explained. Superior resolution capabilities of Capillary Electrophoresis leading to clearly defined hemoglobin fraction separation, ease of HbA1c and Hb testing operation and results interpretation will also be discussed.

Date & Time Oct. 27 (Thu.), 16:40-17:40 Room Room D Language Eng
Chair(s)
  1. Hanah Kim, Konkuk University School of Medicine, Korea
Speaker(s)
  1. Superior resolution Capillary Electrophoresis technology for Hemoglobinopathy screening and accurate HbA1c measurement
    Ivan Lam Chee Ren, Scientific Affairs Manager, Sebia APAC, Singapore

[EW14]
Illumina Korea

Liquid biopsy enables comprehensive analysis of circulating cell-free DNA (cfDNA) in plasma, providing a noninvasive approach for profiling solid tumors. Comprehensive Genome Profiling (CGP) ctDNA assay targets 523 genes associated with solid tumors and is capable of profiling copy number variants, fusions, microsatellite instability, and tumor mutation burden as well as short variants. Validation of CGP ctDNA was performed on the NovaSeqTM 6000 and DRAGENTM platform using various reference material and clinical specimen. OncoKBTM API was adjunctively used to annotate and filter variants provided by DRAGENTM. CGP ctDNA is an effective and versatile assay for clinical use.

Date & Time Oct. 27 (Thu.), 16:40-17:40 Room Room E Language Eng
Chair(s)
  1. Chang-Seok Ki, GC Genome, Korea
Speaker(s)
  1. Introduction of Illumina oncology research products -TruSight Oncology 500 portfolio
    Eun-goo Jeong, Sr. Sales specialist, Illumina Korea
  2. Experience of Validating Comprehensive Genome Profiling (CGP) ctDNA Assay for Clinical Use
    Young-gon Kim, Samsung Medical Center, Korea

[EW15]
SD Biosensor, Inc.

Invasive pneumococcal diseases were responsible for 9.6 cases and 1.06 deaths per 100,000 people, according to the 2018 CDC report. The WHO suggests vaccination, rapid diagnosis, and appropriate antibiotic treatment for Streptococcus pneumoniae infection to reduce
mortality. Traditional bacterial culturing has difficulties confirming the causative organism in previous antibiotic therapy. Therefore, urine antigen tests are recommended for precise and early management. This presentation aims to explain the diagnostic strategies for invasive pneumococcal infection from a laboratory perspective and to share the result of our recent study to estimate the performance of pneumococcal urine antigen tests.

Date & Time Oct. 28 (Fri), 08:00-09:00 Room Room A Language Eng
Chair(s)
  1. Jeong Hwan Shin, Inje University College of Medicine, Korea
Speaker(s)
  1. Laboratory-based diagnosis of pneumococcal disease and the role of urine antigen testing
    Hui-Jin Yu, Seoul Medical Center, Korea

[EW18]
Beckman Coulter Korea

- Introduction
- Laboratory workflows: Optimize 32 manual steps
- Preanalytical errors at risk
- 3 second sample tube quality detection
- DxA 5000Fit error identification
- DxA 5000Fit is designed to automated step
- Best configuration to fit your laboratory
- More function, Less footprint
- Summary

Date & Time Oct. 28 (Fri), 11:50-12:50 Room Room A Language Eng
Chair(s)
  1. DongHee Seo, Labgenomics, Korea
Speaker(s)
  1. DxA 5000 Fit : Workflow Automation is a Compact Footprint
    Jinho Yang, Automation supervisor, Beckman Coulter Korea, Korea

[EW19]
Sysmex Korea

If hepatocyte damage persists for a long time, liver fibrosis, which accumulates scars in the liver, progresses. Excessive liver fibrosis causes poor blood flow into the liver, resulting in complications. Liver dysfunction can occur as the number of normal liver cells decreases. It leads to cirrhosis, and in severe cases, hepatocarcinoma.
It is essential to detect liver fibrosis early by examination since it has no symptoms in the early stages.
M2BPGi is one of the liver fibrosis blood tests, and this workshop is to share my experience of managing and monitoring patients with liver fibrosis with the M2BPGi test.

Date & Time Oct. 28 (Fri), 11:50-12:50 Room Room B Language Eng
Chair(s)
  1. Hwan Sub Lim, Seoul Clinical Laboratories, Korea
Speaker(s)
  1. Practical use and usefulness of liver fibrosis blood marker, M2BPGi
    Do Young Kim, Severance Hospital, Korea

[EW21]
BIONEER

BIONEER has been striving to develop optimal molecular diagnostic products that leads to improvements in laboratory environment and operator convenience. We would like to introduce ExiStation™ FA 96/384, a fully automated MDx system
Topic : HIV-1 viral load test on ExiStation™ FA 96/384

Date & Time Oct. 28 (Fri), 11:50-12:50 Room Room D Language Eng
Chair(s)
  1. Seung-Jung Kee, Chonnam National University College of Medicine, Korea
Speaker(s)
  1. ExiStation™ FA 96/384, The fully-automatic MDx system: Overview of the new system with the comparative evaluation
    Young-Hoon Kim, Vice President, BIONEER, Korea

[EW22]
Abbott Rapid Diagnostics, Inc.

Given the importance of co-infections and the coming influenza season, it is essential to recognize the similarities and differences between the symptoms, immunopathogenesis and treatment of SARS-CoV-2 and influenza virus. Measures to reduce transmission of SARS-CoV-2 have been effective in reducing the transmission of other endemic respiratory viruses and bacterial infections in most regions around the world. The longer these periods of "viral or bacterial low-exposure" are, the greater the likelihood of future infectious epidemics, the consequent payment for the “Immunity Debt”. This is due to a growing proportion of "susceptible" people and a decline in population herd immunity when the containment and mitigation measures during the SARS-CoV-2 epidemic are phased out. As many countries decrease the use of such measures, we expect that SARS-CoV-2 will circulate with other respiratory viruses, increasing the probability of co-infections are more likely to occur during future winters.

Date & Time Oct. 28 (Fri), 11:50-12:50 Room Room E Language Eng
Chair(s)
  1. Myungshin Kim, The Catholic University of Korea College of Medicine, Korea
Speaker(s)
  1. Co-infections between SARS-CoV-2 and Influenza
    TarChoon Aw, Changi General Hospital, Singapore

[EW23]
LG Chem, Ltd.

The reference standard for diagnosis of SARS-CoV-2 infection is real-time reverse transcription-polymerase chain reaction (rRT-PCR), which usually requires an RNA extraction step prior to nucleic acid amplification. The AdvanSure™ One-Stop COVID-19 Plus Kit (AdvanSure™; LG Chem, Seoul, Korea) is a newly developed rRT-PCR assay that can detect SARS-CoV-2 within 90 min without an RNA extraction step. We evaluated the performance of the AdvanSure™ assay in comparison with the PowerChek™ SARS-CoV-2 Real-time PCR Kit (PowerChek™; Kogene Biotech, Seoul, Korea) and shared the results with scientific community.

Date & Time Oct. 28 (Fri), 13:00-14:00 Room Room C Language Eng
Chair(s)
  1. Chang Kyu Lee, Korea University College of Medicine, Korea
Speaker(s)
  1. AdvanSure™ one-Stop COVID-19 plus kit for rapid and accurate detection of SARS-CoV-2 without RNA extraction
    Tae Yeul Kim, Laboratory Medicine and Genetics, Samsung Medical Center, Korea

[EW24]
QIAGEN Korea Ltd.

World Health Organization (WHO) recognizes transplant patients, those on hemodialysis, with silicosis or those considered for anti-TNFa therapy at high risk of developing active TB thus necessitating testing for Latent TB infection (LTBI) in clinical settings. In his talk, Dr Vladyslav Nikolayevskyy will provide an overview of the policies, practices and recent publications on LTBI management in clinical settings focusing on high risk patients groups and those on biologics treatment in particular. He will also discuss new preventive treatment regimens and the use of laboratory-based TB interferon-gamma release assays (IGRAs) as a primary screening method.

Date & Time Oct. 28 (Fri), 13:00-14:00 Room Room D Language Eng
Chair(s)
  1. Management of latent TB infection in clinical settings: role of IGRA assays
Speaker(s)
  1. Management of Latent TB infection in clinical settings: role of IGRA assays
    Vladyslav Nikolayevskyy , Medical Affairs – Infectious Diseases and TB, QIAGEN Manchester Ltd, United Kingdom